DK2699910T3 - A method for determining ligand binding to a target protein using a thermal shift assay - Google Patents
A method for determining ligand binding to a target protein using a thermal shift assay Download PDFInfo
- Publication number
- DK2699910T3 DK2699910T3 DK12717826.7T DK12717826T DK2699910T3 DK 2699910 T3 DK2699910 T3 DK 2699910T3 DK 12717826 T DK12717826 T DK 12717826T DK 2699910 T3 DK2699910 T3 DK 2699910T3
- Authority
- DK
- Denmark
- Prior art keywords
- target protein
- protein
- ligand
- sample
- temperature
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 651
- 102000004169 proteins and genes Human genes 0.000 title claims description 647
- 239000003446 ligand Substances 0.000 title claims description 224
- 238000000034 method Methods 0.000 title claims description 129
- 238000002849 thermal shift Methods 0.000 title description 15
- 210000004027 cell Anatomy 0.000 claims description 114
- 238000002844 melting Methods 0.000 claims description 93
- 230000008018 melting Effects 0.000 claims description 93
- 239000000523 sample Substances 0.000 claims description 69
- 238000012360 testing method Methods 0.000 claims description 57
- 230000009089 cytolysis Effects 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 43
- 229940079593 drug Drugs 0.000 claims description 42
- 239000012521 purified sample Substances 0.000 claims description 42
- 238000001556 precipitation Methods 0.000 claims description 40
- 238000001914 filtration Methods 0.000 claims description 33
- 238000001514 detection method Methods 0.000 claims description 26
- 238000005119 centrifugation Methods 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 238000000926 separation method Methods 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 14
- 238000009630 liquid culture Methods 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 8
- 238000004949 mass spectrometry Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 239000013610 patient sample Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000012805 animal sample Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 description 49
- 238000010438 heat treatment Methods 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 230000002708 enhancing effect Effects 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 21
- 108010022394 Threonine synthase Proteins 0.000 description 20
- 238000007792 addition Methods 0.000 description 19
- 239000006166 lysate Substances 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 230000002255 enzymatic effect Effects 0.000 description 17
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 16
- 230000003993 interaction Effects 0.000 description 16
- 239000000020 Nitrocellulose Substances 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 229920001220 nitrocellulos Polymers 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 239000011148 porous material Substances 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 239000012139 lysis buffer Substances 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 10
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 10
- 102000005497 Thymidylate Synthase Human genes 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 102000004419 dihydrofolate reductase Human genes 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000013592 cell lysate Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000006641 stabilisation Effects 0.000 description 9
- 239000006180 TBST buffer Substances 0.000 description 8
- 239000003596 drug target Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 7
- RYWCQJDEHXJHRI-XJMXIVSISA-N 2-[3-[5-[6-[3-[3-(carboxymethyl)phenyl]-4-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexyl]-2-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]phenyl]acetic acid Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC(C(=C1)C=2C=C(CC(O)=O)C=CC=2)=CC=C1CCCCCCC(C=C1C=2C=C(CC(O)=O)C=CC=2)=CC=C1O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RYWCQJDEHXJHRI-XJMXIVSISA-N 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012160 loading buffer Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 7
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000006137 Luria-Bertani broth Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 102000003923 Protein Kinase C Human genes 0.000 description 5
- 108090000315 Protein Kinase C Proteins 0.000 description 5
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 229960004432 raltitrexed Drugs 0.000 description 5
- 239000013074 reference sample Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 4
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 4
- 108010014251 Muramidase Proteins 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000003019 stabilising effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000011880 melting curve analysis Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012421 spiking Methods 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- -1 cell debris Proteins 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 108091007999 druggable proteins Proteins 0.000 description 2
- 102000038037 druggable proteins Human genes 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940040511 liver extract Drugs 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108020005087 unfolded proteins Proteins 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- XXLAEKOWCYJOKK-UHFFFAOYSA-N PI3-Kinase alpha Inhibitor 2 Chemical compound OC1=CC=CC(C=2N=C3C=CSC3=C(N3CCOCC3)N=2)=C1 XXLAEKOWCYJOKK-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- SJOQNHYDCUXYED-UHFFFAOYSA-K trichlorolutetium;hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Lu+3] SJOQNHYDCUXYED-UHFFFAOYSA-K 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/32—Extraction; Separation; Purification by precipitation as complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9446—Antibacterials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9466—Antidepressants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9473—Anticonvulsants, e.g. phenobarbitol, phenytoin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Computational Biology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1106548.9A GB201106548D0 (en) | 2011-04-18 | 2011-04-18 | A method for determining ligand binding to a target protein using a thermal shift assahy |
| PCT/GB2012/050853 WO2012143714A1 (en) | 2011-04-18 | 2012-04-18 | Methods for determining ligand binding to a target protein using a thermal shift assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2699910T3 true DK2699910T3 (en) | 2016-04-18 |
Family
ID=44147179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12717826.7T DK2699910T3 (en) | 2011-04-18 | 2012-04-18 | A method for determining ligand binding to a target protein using a thermal shift assay |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8969014B2 (enExample) |
| EP (1) | EP2699910B1 (enExample) |
| JP (1) | JP6032715B2 (enExample) |
| KR (1) | KR101940342B1 (enExample) |
| CN (1) | CN103733067B (enExample) |
| AU (1) | AU2012246069B2 (enExample) |
| CA (1) | CA2833076C (enExample) |
| DK (1) | DK2699910T3 (enExample) |
| ES (1) | ES2566637T3 (enExample) |
| GB (2) | GB201106548D0 (enExample) |
| MY (1) | MY171913A (enExample) |
| SG (1) | SG194137A1 (enExample) |
| WO (1) | WO2012143714A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9523693B2 (en) | 2011-04-18 | 2016-12-20 | Biotarget Engagement Interest Group Ab | Methods for determining ligand binding to a target protein using a thermal shift assay |
| GB201106548D0 (en) | 2011-04-18 | 2011-06-01 | Evitraproteoma Ab | A method for determining ligand binding to a target protein using a thermal shift assahy |
| CN103645324B (zh) * | 2013-12-03 | 2017-02-15 | 胡朝阳 | 基于细胞热转移技术的高通量药物靶点筛选方法 |
| GB2524519B (en) | 2014-03-25 | 2019-11-06 | Pelago Bioscience AB | Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay |
| WO2016028804A1 (en) * | 2014-08-21 | 2016-02-25 | Discoverx Corporation | Homogenous thermal shift ligand binding assay |
| WO2016127100A1 (en) | 2015-02-05 | 2016-08-11 | Promega Corporation | Luciferase-based thermal shift assays |
| US11024492B2 (en) | 2015-07-07 | 2021-06-01 | Institute For Systems Biology | Method to obtain unbiased identification of interaction of test compounds with the proteome |
| CN105424928B (zh) * | 2015-11-11 | 2017-05-17 | 山西隆克尔生物制药有限公司 | 一种检测猪繁殖与呼吸综合征病毒抗体的免疫层析条及其制备方法和应用 |
| WO2017206041A1 (zh) * | 2016-05-31 | 2017-12-07 | 王帅 | 测定细胞内配体靶蛋白相互作用持久力的方法 |
| US11567074B2 (en) * | 2016-09-26 | 2023-01-31 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods for identifying proteins that bind ligands |
| KR101862198B1 (ko) * | 2016-09-30 | 2018-05-30 | (주)스파크바이오파마 | 2차원 겔 전기영동에서의 열 안정성 변화-기반 형광 차이를 이용한 표적 단백질의 규명 방법 |
| US11630110B2 (en) | 2017-08-18 | 2023-04-18 | Agency For Science, Technology And Research | Methods to identify protein interaction |
| EP3575416A1 (en) * | 2018-06-01 | 2019-12-04 | InfanDx AG | Detection of target molecules by determining the melting temperature of a recognition module |
| GB201814451D0 (en) * | 2018-09-05 | 2018-10-17 | Valerie Nicholas Carl Kristoffer | Methods |
| CN112924693B (zh) * | 2019-12-06 | 2022-09-27 | 中国科学院大连化学物理研究所 | 一种上清和沉淀协同定量的蛋白质热稳定性分析方法 |
| CN112924694A (zh) * | 2019-12-06 | 2021-06-08 | 中国科学院大连化学物理研究所 | 一种无歧视的蛋白质热稳定性分析方法 |
| JP7502861B2 (ja) * | 2019-12-27 | 2024-06-19 | 旭化成株式会社 | 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法 |
| CN111551749A (zh) * | 2020-06-12 | 2020-08-18 | 郑州大学 | 一种鉴定药物靶蛋白的方法 |
| CN114076826A (zh) * | 2020-08-20 | 2022-02-22 | 中国科学院大连化学物理研究所 | 一种微球辅助的基于蛋白加热沉淀的药物靶蛋白筛选方法 |
| EP4378586A1 (en) | 2022-12-01 | 2024-06-05 | Bayer AG | Integrated system for chemical, biochemical, or biological reactions in a microplate submitted to a temperature gradient |
| WO2024261269A1 (en) | 2023-06-22 | 2024-12-26 | Omicscouts Gmbh | Method for detecting ligand-target interactions using solvent- induced precipitation in intact cells |
| CN116577472B (zh) * | 2023-07-12 | 2023-10-31 | 中国中医科学院中药研究所 | 植物细胞环境蛋白组学分析方法及应用 |
| GB2634749A (en) * | 2023-10-18 | 2025-04-23 | Proteinera Holding Ab | Methods for detecting apoptosis |
| GB2634751A (en) * | 2023-10-18 | 2025-04-23 | Proteinera Holding Ab | Methods for detecting protein cleavage |
| WO2025247735A1 (en) | 2024-05-29 | 2025-12-04 | Bayer Aktiengesellschaft | Solvent induced precipitation (sip) assays using specific solvent combinations |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4780409A (en) | 1985-05-02 | 1988-10-25 | Genetic Systems Corporation | Thermally induced phase separation immunoassay |
| US6020141A (en) * | 1996-05-09 | 2000-02-01 | 3-Dimensional Pharmaceuticals, Inc. | Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimization |
| WO1999024050A1 (en) * | 1997-11-12 | 1999-05-20 | 3-Dimensional Pharmaceuticals, Inc. | High throughput method for functionally classifying proteins identified using a genomics approach |
| US6171850B1 (en) | 1999-03-08 | 2001-01-09 | Caliper Technologies Corp. | Integrated devices and systems for performing temperature controlled reactions and analyses |
| US6376180B1 (en) * | 1999-12-09 | 2002-04-23 | Pharmacia & Upjohn Company | Methods of identifying compounds that bind to target species under isothermal denaturing conditions |
| JP2004537047A (ja) * | 2001-06-14 | 2004-12-09 | アナディーズ ファーマスーティカルズ，アイエヌシー． | 標的分子のリガンドをスクリーニングする方法 |
| EP2357237A1 (en) * | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| GB0315525D0 (en) | 2003-07-02 | 2003-08-06 | Nordlund Paer | A method of screening |
| JP4695851B2 (ja) | 2003-07-10 | 2011-06-08 | シチズンホールディングス株式会社 | マイクロ化学チップ温度調節装置 |
| JP5502275B2 (ja) | 2004-05-02 | 2014-05-28 | フルイディグム コーポレイション | 熱反応デバイスおよびその熱反応デバイスの使用方法 |
| WO2006110292A2 (en) * | 2005-03-25 | 2006-10-19 | The Regents Of The University Of California | Temperature-triggered immobilization and purification of antibodies |
| LT5504B (lt) * | 2006-08-02 | 2008-06-25 | Biotechnologijos Institutas | Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti |
| US20100256342A1 (en) * | 2008-08-12 | 2010-10-07 | Francis Raymond Salemme | Protein nodes for controlled nanoscale assembly |
| JP2012531582A (ja) * | 2009-06-26 | 2012-12-10 | アトラス・アンティボディーズ・アクチボラゲット | 免疫検出性の改善 |
| US8476081B2 (en) * | 2009-09-21 | 2013-07-02 | Janssen Pharmaceutica Nv | Assay for evaluating affinity and specificity of ligand-albumin binding |
| US9523693B2 (en) | 2011-04-18 | 2016-12-20 | Biotarget Engagement Interest Group Ab | Methods for determining ligand binding to a target protein using a thermal shift assay |
| GB201106548D0 (en) | 2011-04-18 | 2011-06-01 | Evitraproteoma Ab | A method for determining ligand binding to a target protein using a thermal shift assahy |
-
2011
- 2011-04-18 GB GBGB1106548.9A patent/GB201106548D0/en not_active Ceased
-
2012
- 2012-04-18 ES ES12717826.7T patent/ES2566637T3/es active Active
- 2012-04-18 KR KR1020137030379A patent/KR101940342B1/ko active Active
- 2012-04-18 DK DK12717826.7T patent/DK2699910T3/en active
- 2012-04-18 WO PCT/GB2012/050853 patent/WO2012143714A1/en not_active Ceased
- 2012-04-18 EP EP12717826.7A patent/EP2699910B1/en active Active
- 2012-04-18 JP JP2014505717A patent/JP6032715B2/ja active Active
- 2012-04-18 SG SG2013075072A patent/SG194137A1/en unknown
- 2012-04-18 AU AU2012246069A patent/AU2012246069B2/en active Active
- 2012-04-18 CN CN201280025677.XA patent/CN103733067B/zh active Active
- 2012-04-18 MY MYPI2013003781A patent/MY171913A/en unknown
- 2012-04-18 GB GB1206834.2A patent/GB2490404B/en active Active
- 2012-04-18 CA CA2833076A patent/CA2833076C/en active Active
-
2013
- 2013-10-18 US US14/057,920 patent/US8969014B2/en active Active
-
2015
- 2015-01-22 US US14/602,993 patent/US9528996B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG194137A1 (en) | 2013-11-29 |
| ES2566637T3 (es) | 2016-04-14 |
| AU2012246069B2 (en) | 2016-09-22 |
| CN103733067A (zh) | 2014-04-16 |
| HK1192612A1 (zh) | 2014-08-22 |
| CA2833076A1 (en) | 2012-10-26 |
| GB2490404B (en) | 2013-11-06 |
| AU2012246069A1 (en) | 2013-10-31 |
| GB2490404A (en) | 2012-10-31 |
| GB201106548D0 (en) | 2011-06-01 |
| JP2014513293A (ja) | 2014-05-29 |
| GB201206834D0 (en) | 2012-05-30 |
| US9528996B2 (en) | 2016-12-27 |
| KR20140033366A (ko) | 2014-03-18 |
| CN103733067B (zh) | 2016-01-13 |
| EP2699910A1 (en) | 2014-02-26 |
| KR101940342B1 (ko) | 2019-01-18 |
| MY171913A (en) | 2019-11-06 |
| JP6032715B2 (ja) | 2016-11-30 |
| US20140057368A1 (en) | 2014-02-27 |
| EP2699910B1 (en) | 2016-03-09 |
| WO2012143714A1 (en) | 2012-10-26 |
| CA2833076C (en) | 2020-07-14 |
| US8969014B2 (en) | 2015-03-03 |
| US20150140575A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2699910T3 (en) | A method for determining ligand binding to a target protein using a thermal shift assay | |
| US9523693B2 (en) | Methods for determining ligand binding to a target protein using a thermal shift assay | |
| Feng et al. | Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration | |
| CN101512016B (zh) | 可检测的核酸标签 | |
| Henneberg et al. | Activity-based profiling of cullin–RING E3 networks by conformation-specific probes | |
| Rajan et al. | Generation of an alpaca-derived nanobody recognizing γ-H2AX | |
| JP2006519013A (ja) | 基転移反応のアッセイ方法 | |
| CA2942605C (en) | Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay | |
| WO2017206041A1 (zh) | 测定细胞内配体靶蛋白相互作用持久力的方法 | |
| HK1192612B (en) | Methods for determining ligand binding to a target protein using a thermal shift assay | |
| Schwalm et al. | Targeting LC3/GABARAP for degrader development and autophagy modulation | |
| JP2020068746A (ja) | バイオセンサー | |
| Chea et al. | Characterizing cellular proteins with in-cell fast photochemical oxidation of proteins | |
| Colom et al. | Nucleoporin-binding nanobodies that either track or inhibit nuclear pore complex assembly | |
| EP2801622A1 (en) | Multi-tag reporter system | |
| US20240302379A1 (en) | Methods for identifying and monitoring interactions of protein with ligand | |
| Park et al. | Protein–Protein Interactions | |
| HK1228003A1 (en) | Method for identifying a biomarker indicative of a reduced drug response using a thermal shift assay | |
| KR20140043418A (ko) | 벤조안트라센 오염 검출을 위한 마커 및 키트 |